1-8 of 8
Cyril H. Benes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma

Daniel A.R. Heisey, Sheeba Jacob, Timothy L. Lochmann, Richard Kurupi, Maninderjit S. Ghotra, Marissa L. Calbert, Mayuri Shende, Yuki Kato Maves, Jennifer E. Koblinski, Mikhail G. Dozmorov, Sosipatros A. Boikos, Cyril H. Benes, Anthony C. Faber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1868–1879.
https://doi.org/10.1158/1535-7163.MCT-20-0489
Published: 01 October 2021
View article titled, Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Open the PDF for Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma in another window
Includes: Supplementary data
Journal Articles

Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Krista M. Dalton, Kateryna Krytska, Timothy L. Lochmann, Renata Sano, Colleen Casey, Alessia D'Aulerio, Qasim A. Khan, Giovanna Stein Crowther, Colin Coon, Jinyang Cai, Sheeba Jacob, Richard Kurupi, Bin Hu, Mikhail Dozmorov, Patricia Greninger, Andrew J. Souers, Cyril H. Benes, Yael P. Mossé, Anthony C. Faber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (8): 1400–1411.
https://doi.org/10.1158/1535-7163.MCT-20-0710
Published: 01 August 2021
View article titled, Venetoclax-based Rational Combinations are Effective in Models of <em>MYCN</em>-amplified Neuroblastoma
Open the PDF for Venetoclax-based Rational Combinations are Effective in Models of <em>MYCN</em>-amplified Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract A188: Harnessing synthetic lethality to predict the response to cancer treatments

Joo S. Lee, Avinash Das, Livnat Jerby-Arnon, Rand Arafeh, Matthew Davidson, Arnaud Amzallag, Seung Gu Park, Kuoyuan Cheng, Welles Robinson, Dikla Atias, Chani Stossel, Ella Buzhor, Gidi Stein, Joshua J. Waterfall, Paul S. Meltzer, Talia Golan, Sridhar Hannenhalli, Eyal Gottlieb, Cyril H. Benes, Yardena Samuels, Emma Shanks, Eytan Ruppin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A188.
https://doi.org/10.1158/1535-7163.TARG-17-A188
Published: 01 January 2018
View article titled, Abstract A188: Harnessing synthetic lethality to predict the response to cancer treatments
Journal Articles

Abstract PR09: Harnessing synthetic lethality to predict clinical outcomes of cancer treatment

Joo Sang Lee, Avinash Das, Livnat Jerby-Arnon, Dikla Atias, Arnaud Amzallag, Cyril H. Benes, Talia Golan, Eytan Ruppin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10_Supplement): PR09.
https://doi.org/10.1158/1538-8514.SYNTHLETH-PR09
Published: 02 October 2017
View article titled, Abstract PR09: Harnessing synthetic lethality to predict clinical outcomes of cancer treatment
Journal Articles

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Stuart W. Ember, Que T. Lambert, Norbert Berndt, Steven Gunawan, Muhammad Ayaz, Marilena Tauro, Jin-Yi Zhu, Paula J. Cranfill, Patricia Greninger, Conor C. Lynch, Cyril H. Benes, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, Ernst Schönbrunn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1054–1067.
https://doi.org/10.1158/1535-7163.MCT-16-0568-T
Published: 01 June 2017
View article titled, Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Open the PDF for Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics in another window
Includes: Supplementary data
Journal Articles

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason T. Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Toshi Shioda, Dora Dias-Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR09.
https://doi.org/10.1158/1535-7163.PMS-PR09
Published: 01 May 2014
View article titled, Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models
Journal Articles

Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Erin M. Coffee, Anthony C. Faber, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy J. Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C263.
https://doi.org/10.1158/1535-7163.TARG-13-C263
Published: 01 November 2013
View article titled, Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Journal Articles

Abstract A29: PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Hiromichi Ebi, Carlotta Costa, Anthony Faber, Dejan Juric, Patricia Della Pelle, Youngchul Song, Seiji Yano, Mari Mino-Kenudson, Cyril H. Benes, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A29.
https://doi.org/10.1158/1535-7163.TARG-13-A29
Published: 01 November 2013
View article titled, Abstract A29: PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.